key: cord-0933110-1009m2y8
authors: Kim, Do Hyun; Kim, Sung Won; Kang, Minju; Hwang, Se Hwan
title: Efficacy of topical steroids for the treatment of olfactory disorders caused by COVID‐19: A systematic review and meta‐analysis
date: 2022-04-06
journal: Clin Otolaryngol
DOI: 10.1111/coa.13933
sha: e457f95c2c2fd10d6dbeaebb6142c55ef0bf59b0
doc_id: 933110
cord_uid: 1009m2y8

OBJECTIVES: The aim of this study was to assess the effect of topical steroids on acute‐onset olfactory dysfunction in patients infected with COVID‐19. DESIGN AND SETTING: Systematic review and meta‐analysis of cohort studies. PARTICIPANTS: Patients infected with COVID‐19. MAIN OUTCOME MEASURES: PubMed, Embase, the Web of Science, SCOPUS, Cochrane database and Google Scholar were searched for articles up to September 2021. We analysed studies comparing the improvement of olfactory dysfunction between topical steroid treatment and control groups (placebo or no treatment). In addition, we performed a subgroup analysis by study type. RESULTS: The improvement of olfactory score at 2 (standardised mean difference [SMD] = 0.7272, 95% confidence interval = [0.3851, 1.0692], p < .0001, I (2) = 62.1%) and 4 weeks post‐treatment (SMD = 1.0440 [0.6777, 1.4102], p < .0001, I (2) = 61.2%) was statistically greater in the treatment than control group. However, there was no significant difference (odds ratio [OR] = 1.4345 [0.9525, 2.1604], p = .0842, I (2) = 45.4%) in the incidence of fully recovery from anosmia/hyposmia between the treatment and control groups. In subgroup analysis, there were no significant differences in the improvement of olfactory score at 4 weeks post‐treatment (OR = 0.6177 [0.1309, 1.1045] vs. 0.1720 [0.8002, 1.5438], p = .0761) or the incidence of full recovery from anosmia/hyposmia (OR = 1.8478 [0.6092, 5.6053] vs. 1.3784 [0.8872, 2.1414], p = .8038) between randomised and non‐randomised controlled trials. CONCLUSIONS: Although this meta‐analysis found that topical steroids improved the acute‐onset olfactory dysfunction caused by COVID‐19, there was no difference in the rate of full olfactory recovery between treated and control patients.

anosmia. 5 Given the high global prevalence of COVID-19, olfactory dysfunction may also be an important issue in otolaryngology, and long-lasting loss of smell lead to comorbidities such as depression and cognitive impairment. 5 For this reason, there is a need to identify effective treatments that promote spontaneous recovery of olfactory function. 6 No intervention shows a clear (i.e. evidence-based) benefit, although olfactory training is generally effective in improving olfaction in COVID-19 patients. 7 Oral or topical corticosteroids are typically used to treat olfactory disorders. 8 However, systemic corticosteroid for COVID-19 patients is not recommended due to the potential for immunosuppression or delayed viral clearance. 9 Meanwhile, the effect of topical corticosteroids on olfaction recovery in patients with olfactory impairment caused by COVID-19 is still controversial. 10, 11 Despite these clinical controversies, no systematic review of studies examining the effects of topical steroids on olfactory dysfunction in COVID-19 patients has been published.

Therefore, the purpose of this study was to evaluate olfactory recovery and the efficacy of topical steroids for COVID-19 patients with olfactory dysfunction.

We searched the PubMed, SCOPUS, Embase, Web of Science, Google Scholar and Cochrane databases for relevant studies.

We retrieved all prospective articles published in English prior to September 2021. COVID-19, SARS-CoV-2, anosmia, hyposmia, olfactory, smell, olfactory disorders, olfactory dysfunctions, recovery, olfactory test, steroid therapy, nasal spray, corticosteroids and treatment were the search terms and keywords (Table S1 ). Two independent researchers reviewed and screened the titles and abstracts of all identified studies, and excluded those not related to topical steroids in patients testing positive for COVID-19 and having acute-onset (<2 weeks) olfactory dysfunction. If the abstract alone was not sufficient to determine whether to include a study, the full text was checked. Studies were excluded if they described long-lasting olfactory dysfunction that onset after more than 3 weeks. In Figure 1 , we present a flow chart of the study selection process. The study protocol was registered at the Open Science Framework (https://osf. io/m5gkd/). This study was prepared in accordance with the recommendations of the Priority Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines.

We extracted the following data from the eligible studies: number of patients, scale used for analysing olfactory disorders, incidence (percentage) of patients showing a full recovery from olfactory dysfunction and p-values for comparisons between topical steroid and control groups. The data were organised using a standardised format. 4, 12 The outcomes of interest were the post-treatment olfactory score (2 and 4 weeks after the initiation of treatment were analysed referring to the common analysis time point of the included papers) and percentage of patients with a full recovery. 7, 10, 11, 13, 14 These outcomes were compared between the treatment (topical steroid) and control groups; the latter were administered either saline or nothing. When the original data were expressed as continuous variables, the meta-analysis was performed using the standardised mean difference (SMD). In our study, this method was chosen to calculate effect sizes due to the absence of a standardised scale used across all studies to assess olfactory function (self-reported olfactory score system, VAS, Iranian version of UPSIT and Sniffin' Sticks tests). The individual mean difference (treatment outcome minus control outcome) is assessed with the size and standard deviation of each study. This method allows a precise estimate of the treatment effect and summates it into a single outcome (SMD). An effect size of approximately 0.2 is considered a small effect, while 0.5 is considered a medium effect and 0.8 a large and clinically significant effect. The quality assessment of the included randomised controlled studies was conducted using the Cochrane Risk of bias tool. 15 The Newcastle-Ottawa Scale was used to assess non-randomised controlled studies with scores ranging from 0 to 9.

Meta-analyses were conducted using R statistical software (R Foundation for Statistical Computing). Continuous variables were analysed using the standardised mean difference (SMD). We used this method to calculate the effect sizes because, among the included studies, no standardised measure was used for evaluating olfactory function, such as self-rated scores, a visual analogue scale, or the Sniffin' Sticks test. In all other cases, odds ratios (ORs) were calculated. We also conducted sensitivity analyses to assess the effect of each study on the overall meta-analysis results.

• The prevalence of olfactory disorders due to COVID-19 is high.

• No intervention shows a clear benefit in improving olfaction in COVID-19 patients.

• Systemic corticosteroid for COVID-19 patients is usually not recommended.

• Topical steroids could improve the acute-onset olfactory dysfunction caused by COVID-19.

• No significant difference in olfactory score in the endpoint after topical steroids treatment.

Of 696 articles initially identified, 5 were included in the final analysis; the study characteristics are listed in Table 1 , and bias assessment results are presented in Table S2 and S3. We did not evaluate publication bias because the number of studies included was not sufficient to generate a funnel plot or perform advanced regression analyses.

The treatment group showed a significantly higher olfactory score 

We performed a sensitivity analysis to evaluate the effects on the outcomes of the meta-analysis of excluding individual studies. In all cases, the results were consistent with those described above. • UPSIT: anosmia [0-9], severe microsmia [10] [11] [12] [13] mild microsmia [14] [15] [16] [17] [18] and normosmia [19] [20] [21] [22] [23] [24] 

Anosmia induced by an upper respiratory viral infection is a common cause of olfactory disorder. 16 Prior to the COVID-19 epidemic, the prevalence of olfactory dysfunction due to upper respiratory tract infection in the general population was approximately 3%−20%. 17 However, the worldwide prevalence of olfactory disorder in COVID-19 patients is 46%, 18 with estimates ranging from 50% to 85%. Prevalence is particularly high in Europe and North

America. 14 Therefore, olfactory dysfunction is a representative finding of COVID-19 patients and is in fact typically the only clinical symptom. 4 However, it is not yet known whether the proportion of patients with olfactory dysfunction is significantly higher than that of other viral infections.

In general, olfactory disorders caused by viruses arise due to local inflammation of the nasal cavity and olfactory nerve damage; similar mechanisms likely explain olfactory disorders related to COVID-19

infection. 19 It has been suggested that anosmia that recovers within a short time can be attributed to a transient inflammatory process in the olfactory epithelium, whereas neuronal damage is responsible for long-lasting anosmia. 20 When the COVID-19 pandemic spread to Europe, many patients were advised to perform olfactory training, a therapeutic method without complications promoting neuronal plasticity in the olfactory system. 14 have beneficial anti-inflammatory effects. 21, 22 In addition to reducing local inflammation, intranasal corticosteroids may improve olfaction by modulating the function of olfactory receptor neurons through their effects on Na-K-ATPase enzyme activity. 23 Although the analysis on this topic was conducted in the Cochrane review, additional evidence is needed as the analysis was conducted based on a single study. 24 We attempted to add evidence by further analysing recently reported articles.

In our study, the SMD for the measurements regarding the olfactory scoring at 2 and 4 weeks after treatment was mostly around 0.8, which meant that these effect sizes were clinically significant. While provide more reliable assessments of olfactory symptoms than selfreport measures, and inconsistency in the methods used for olfactory assessment can lead to heterogeneity in the results. 7 Interestingly, two of the studies included in our meta-analysis showed that topical steroids were either not significantly more effective or less effective than the control, although two others showed that steroids were an effective treatment. The former two studies had younger patient cohorts. It has been reported that olfaction in younger patients recovers faster than in older ones; age is an important prognostic factor with respect to recovery and regeneration of the olfactory epithelium. 10, 13 Therefore, topical steroids might be of more benefit for older individuals. Moreover, patients whose pathogenesis is neurological might remain anosmic or hyposmic.

The present meta-analysis had several limitations. First, it included studies using different methods and steroids for olfactory recovery. However, since the study procedures were similar between the intervention and control groups for the individual RCTs, any confounding effect on our analysis was likely to be small. 25 

Topical steroids improve the acute-onset olfactory dysfunction caused by COVID-19, although we found no statistically significant difference in the rate of full olfactory recovery between patients receiving and controls. 

The authors have declared that no competing interests exist. [Correction added on April 13, 2022, after first online publication:

Peer review history is not available for this article, so the peer review history statement has been removed.]

This meta-analysis extracted data from previously published articles. 

Real-time tracking of selfreported symptoms to predict potential COVID-19

The close relationship between sudden loss of smell and COVID-19

Anosmia and dysgeusia in COVID-19: a systematic review

Predictive value of olfactory and taste symptoms in the diagnosis of COVID-19: a systematic review and meta-analysis

Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell

Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients

Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: a randomized, double blind clinical trial

Clinical practice guidelines for the management of olfactory dysfunction -Secondary publication

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: a randomised double-blind placebo-controlled study

Comparison of the healing effect of nasal saline irrigation with triamcinolone acetonide versus nasal saline irrigation alone in COVID-19 related olfactory dysfunction: a randomized controlled study

The efficacy of hypotensive agents on intraoperative bleeding and recovery following general anesthesia for nasal surgery: a network meta-analysis

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial

Short-term efficacy and safety of oral and nasal corticosteroids in COVID-19 patients with olfactory dysfunction: a European multicenter study

The cochrane collaboration's tool for assessing risk of bias in randomised trials

ENT manifestation in COVID-19 patients

Anosmia-a clinical review

Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): a meta-analysis of 27,492 patients

COVID-19 and anosmia: a review based on up-to-date knowledge

Perspectives in olfactory loss following viral infections of the upper respiratory tract

Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia

Using intranasal corticosteroids

Assessment of smell and taste in patients with allergic rhinitis

Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction

Evaluating the role of topical tranexamic acid in cancers of the head-and-neck: a single-center randomized controlled trial

More than smell-COVID-19 is associated with severe impairment of smell, taste, and chemesthesis